---
title: "Rhythm Pharmaceuticals CFO Sells Over 7,000 Shares"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275836866.md"
description: "Rhythm Pharmaceuticals' CFO, Smith Hunter C, sold 7,071 shares of common stock on February 10-12, 2026, for a total of $708,575. Following the sales, he retains ownership of 118,466 shares. The transactions were reported in SEC Form 4."
datetime: "2026-02-13T02:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275836866.md)
  - [en](https://longbridge.com/en/news/275836866.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275836866.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275836866.md) | [English](https://longbridge.com/en/news/275836866.md)


# Rhythm Pharmaceuticals CFO Sells Over 7,000 Shares

Rhythm Pharmaceuticals' Chief Financial Officer, Smith Hunter C, sold a total of 7,071 shares of common stock across multiple transactions on February 10, 11, and 12, 2026. The sales were executed at weighted average prices, indicating multiple transactions at varying prices. The total sale amount was $708,575. Following these transactions, Smith Hunter C directly owns 118,466 shares of Rhythm Pharmaceuticals. All transactions were direct ownership.

Reporter Name

Smith Hunter C

Relationship

Chief Financial Officer

Type

Sell

Amount

$708,575

SEC Filing

Form 4

SEC Filing: RHYTHM PHARMACEUTICALS, INC. \[ RYTM \] - Form 4 - Feb. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### 相關股票

- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Rhythm Pharma (RYTM.US)](https://longbridge.com/zh-HK/quote/RYTM.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-HK/news/278776483.md)
- [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/zh-HK/news/278380208.md)
- [Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs](https://longbridge.com/zh-HK/news/278102320.md)
- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/zh-HK/news/278880252.md)
- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/zh-HK/news/278542482.md)